It's great to see that UNICOCELL has decided to pursue a stock listing on the Taiwan Innovation Board. They join nine other domestic companies who have also taken this step in 2023.
 
Taiwan's cell therapy clinical trials are intensely competitive. Leading the race to Phase III clinical trials are 3 industry frontrunners, #Unicocell, Safe Save Medical Cell Sciences & Technology, and MetaTech (AP) Inc .
 
Meanwhile, Raypal Biomedical, Maria Von Medbio, Steminent Biotherapeutics, Transwell Biotech, Ivy Life Sciences, Taiwan Bio Therapeutics, and Lukas Biomedical are gearing up to conclude their Phase II clinical trials.
 
We look forward to hearing about the results as they work towards their goals!
 
Explore the forefront of cutting-edge cell therapies in Taiwan!✨
 
https://lnkd.in/gjcyJwQB
 
#CellTherapy #Innovation #TaiwanInnovationBoard #ClinicalTrials #PhaseIII #HealthcareInnovation #Biotech #TaiwanTech #HealthTech #LifeScience #RegenerativeMedicine